PATENT CLAIM ANALYSIS

Application Number: 16224591
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-07
Patent Classification: ["424", "204100"]

Abstract:
The invention provides compositions and methods for treating human papillomavirus (HPV) infections using a targetable nuclease, which compositions and methods can be used to selectively target the HPV genome or selectively express the targetable nuclease within cells that infected by HPV. By selectively targeting cells infected by HPV, the HPV genome within infected cells, or both, the nuclease is able to cleave the HPV genome thereby inactivating it and rendering it inoperable, interfering with the virus's ability to propagate even where the virus is in a latent stage of infection. Since latent HPV can be cleaved and eradicated from the host cells, compositions and methods of the invention may be used to treat HPV infections and potentially prevent many of the adverse health consequences associated with the papillomavirus.

Claim (Index 23):
The composition of  claim 22 , further comprising a liposome enveloping the RNP.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 98.0
- Lexical Diversity: 1.89189
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14725943', '15167204', '14790748', '16003967', '15250514']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7780414646068843
- 35 USC 102 Novelty (BERT): 0.6114879485381335
- Combined Prediction Score: 0.7613861130000091
- Mean Citation Score: 396.155258
- Max Citation Score: 449.5324
- Similarity Product: 271.04715785841944

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test